The sacral nerve stimulation market was valued at $422.66 million in 2022 and is estimated to reach $702.10 million by 2032, exhibiting a CAGR of 5.2% from 2023 to 2032. Sacral nerve stimulation is a clinical procedure used to treat certain situations associated with bladder and bowel dysfunction, consisting of urinary and fecal incontinence. It involves implantation of a small device, called a neurostimulator, which supplies electrical impulses to the sacral nerves located near the lower back. These sacral nerves are accountable for controlling the muscle tissues involved in bladder and bowel function.
During the sacral nerve stimulation procedure, the neurostimulator is typically implanted under the skin, often in the buttock area. Thin, insulated wires with electrodes at their tips, called leads, are then placed near the sacral nerves. Once the neurostimulator is activated, it delivers mild electrical signals to the sacral nerves, which modulate their activity. The electrical impulses sent by the neurostimulator help to regulate nerve signals, improve communication between the nerves and the bladder or bowel, and restore proper control over these functions. By stimulating the sacral nerves, sacral nerve stimulation aims to improve muscle coordination, reduce episodes of incontinence, and potentially alleviate symptoms of overactive bladder or fecal urgency. The major factors driving the growth of the sacral nerve stimulation market include increase in the number of populaces suffering from urological incontinence conditions, technological advancements in sacral nerve stimulation devices, and rise in adoption of sacral nerve stimulation devices.
The rising overactive bladder or fecal urgency conditions can be debilitating, affecting an individual’s quality of life and thus, requiring long-term effective treatment. Sacral nerve stimulation devices have emerged as an effective treatment option for patients who have not responded to other traditional forms of therapy.
Furthermore, sacral nerve stimulation devices have undergone significant technological advancements, leading to smaller, flexible, and more effective devices. For example, newer devices are now compatible with MRI scans, eliminating the need for device removal during imaging procedures. Furthermore, introduction of rechargeable batteries and wireless capabilities enhances patient comfort and convenience. These technological advancements are anticipated to boost the demand for sacral nerve stimulation devices, as patients and physicians seek more efficient and user-friendly options.
However, the high cost of sacral nerve stimulators and potential risks and complications associated with the procedure act as restraints to the market growth. The high upfront costs limit accessibility, particularly in regions with limited healthcare resources, while concerns about risks and complications are expected to deter potential patients and healthcare providers from adopting this therapy.
Moreover, the global population is aging rapidly, and this demographic shift is expected to drive the demand for sacral nerve stimulation devices. As per the U.S. Census Bureau 2022, more than 56 million adults aged 65 and above live in the U.S., accounting for almost 16.9% of the nation’s population; thus, rise in geriatric population is anticipated to fuel the growth of the market. Furthermore, rise in demand of implantable stimulators owing to its advantages drives the market growth. Thus, the above factors are anticipated to fuel the market growth.
The sacral nerve stimulation market is segmented into product, application, end user, and region. On the basis of product, the market is bifurcated into devices and accessories. On the basis of application, it is categorized into urinary fecal incontinence, chronic anal fissure, and others (overactive bladder syndrome, urinary frequency). On the basis of end user, it is segregated into hospitals, specialty clinics, and others (research centers, ambulatory surgical centers). Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global sacral nerve stimulation market are Medtronic Plc, Beijing PINS Medical Co., Ltd., Saluda Medical Pty Ltd., and Axonics, Inc. The key players have adopted strategies such as acquisition, product launch, and product approval to expand their product portfolio.
During the sacral nerve stimulation procedure, the neurostimulator is typically implanted under the skin, often in the buttock area. Thin, insulated wires with electrodes at their tips, called leads, are then placed near the sacral nerves. Once the neurostimulator is activated, it delivers mild electrical signals to the sacral nerves, which modulate their activity. The electrical impulses sent by the neurostimulator help to regulate nerve signals, improve communication between the nerves and the bladder or bowel, and restore proper control over these functions. By stimulating the sacral nerves, sacral nerve stimulation aims to improve muscle coordination, reduce episodes of incontinence, and potentially alleviate symptoms of overactive bladder or fecal urgency. The major factors driving the growth of the sacral nerve stimulation market include increase in the number of populaces suffering from urological incontinence conditions, technological advancements in sacral nerve stimulation devices, and rise in adoption of sacral nerve stimulation devices.
The rising overactive bladder or fecal urgency conditions can be debilitating, affecting an individual’s quality of life and thus, requiring long-term effective treatment. Sacral nerve stimulation devices have emerged as an effective treatment option for patients who have not responded to other traditional forms of therapy.
Furthermore, sacral nerve stimulation devices have undergone significant technological advancements, leading to smaller, flexible, and more effective devices. For example, newer devices are now compatible with MRI scans, eliminating the need for device removal during imaging procedures. Furthermore, introduction of rechargeable batteries and wireless capabilities enhances patient comfort and convenience. These technological advancements are anticipated to boost the demand for sacral nerve stimulation devices, as patients and physicians seek more efficient and user-friendly options.
However, the high cost of sacral nerve stimulators and potential risks and complications associated with the procedure act as restraints to the market growth. The high upfront costs limit accessibility, particularly in regions with limited healthcare resources, while concerns about risks and complications are expected to deter potential patients and healthcare providers from adopting this therapy.
Moreover, the global population is aging rapidly, and this demographic shift is expected to drive the demand for sacral nerve stimulation devices. As per the U.S. Census Bureau 2022, more than 56 million adults aged 65 and above live in the U.S., accounting for almost 16.9% of the nation’s population; thus, rise in geriatric population is anticipated to fuel the growth of the market. Furthermore, rise in demand of implantable stimulators owing to its advantages drives the market growth. Thus, the above factors are anticipated to fuel the market growth.
The sacral nerve stimulation market is segmented into product, application, end user, and region. On the basis of product, the market is bifurcated into devices and accessories. On the basis of application, it is categorized into urinary fecal incontinence, chronic anal fissure, and others (overactive bladder syndrome, urinary frequency). On the basis of end user, it is segregated into hospitals, specialty clinics, and others (research centers, ambulatory surgical centers). Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global sacral nerve stimulation market are Medtronic Plc, Beijing PINS Medical Co., Ltd., Saluda Medical Pty Ltd., and Axonics, Inc. The key players have adopted strategies such as acquisition, product launch, and product approval to expand their product portfolio.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the sacral nerve stimulation market analysis from 2022 to 2032 to identify the prevailing sacral nerve stimulation market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the sacral nerve stimulation market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global sacral nerve stimulation market trends, key players, market segments, application areas, and market growth strategies.
Additional benefits you will get with this purchase are:
- Quarterly update (only available with the purchase of an enterprise license)
- 5 additional company profiles of your choice, pre- or post-purchase, as a free update.
- Free updated version (once released) with the purchase of a 1-5 or enterprise user license.
- 16 analyst hours of support (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% free customization (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
- Free data pack (Excel version) with the purchase of a 1-5 or enterprise user license.
- Free report update, if the report is 6-12 months old or older.
- 24-hour priority response
- Free industry updates and white papers.
Key Market Segments
By Product
- Devices
- Accessories
By Application
- Urinary and Fecal Incontinence
- Chronic Anal Fissure
- Others
By End User
- Hospitals
- Specialty Clinics
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Axonics, Inc.
- Beijing PINS Medical Co., Ltd.
- Saluda Medical Pty Ltd.
- Medtronic plc
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: SACRAL NERVE STIMULATION MARKET, BY PRODUCT
CHAPTER 5: SACRAL NERVE STIMULATION MARKET, BY APPLICATION
CHAPTER 6: SACRAL NERVE STIMULATION MARKET, BY END USER
CHAPTER 7: SACRAL NERVE STIMULATION MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
The sacral nerve stimulation market is likely to experience a significant growth rate of 5.2% from 2023-2032 owing to increase in demand devices segment. According to this report, the sacral nerve stimulation market was valued at $422.66 million in 2022, and is estimated to reach $702.1 million by 2032, growing at a CAGR of 5.2% from 2023 to 2032.
A sacral nerve stimulator is a medical device that utilizes mild electrical impulses to modulate the sacral nerves, located near the base of the spine. It's employed to treat conditions like urinary and fecal incontinence, as well as pelvic pain and certain disorders affecting pelvic muscles. By regulating nerve signals, the stimulator can enhance control over bladder and bowel function while mitigating discomfort. Surgically implanted, it consists of a generator that emits controlled pulses to influence nerve activity, improving patients' quality of life by addressing these pelvic health issues.
The growth of the sacral nerve stimulation market is primarily being propelled by the escalating prevalence of urological incontinence conditions, encompassing urinary and fecal incontinence, urge incontinence, and chronic anal fissure. These conditions collectively impact a substantial portion of the population, especially the elderly. Age-related factors such as muscle weakness, neurological disorders, and pelvic floor dysfunction significantly contribute to the surge in incontinence cases.
For instance, according to Medscape report in 2023, urinary incontinence increases with age, affecting 38-55% of women older than 60 years and 50-84% of the elderly in long-term care facilities. Females experience a notably higher occurrence of urinary incontinence compared to males, attributed to factors like pregnancy, childbirth, menopause, and anatomical variations in pelvic structures. These specific physiological changes can lead to weakened pelvic floor muscles and compromised bladder control, elevating the vulnerability to urinary incontinence.
The demand for sacral nerve stimulation devices is thus surging as they offer promising solutions to manage these challenging conditions. By directly influencing nerve signals, these devices provide targeted relief and improved control over bladder and bowel functions, enhancing the overall quality of life for affected individuals. As the prevalence of urological incontinence continues to rise, particularly among the aging population, the market for sacral nerve stimulation is expected to witness sustained growth due to its potential to address these pressing healthcare needs.
Moreover, increased investment in healthcare infrastructure development is bolstering the growth of the sacral nerve stimulation market. As healthcare systems expand and modernize, there's a greater emphasis on advanced medical technologies like sacral nerve stimulators. This financial commitment facilitates improved accessibility to these devices and associated treatments, catering to the rising demand for effective solutions to urological incontinence and related conditions.
Furthermore, the trend toward the adoption of implantable sacral nerve stimulation devices over traditional methods has played a crucial role in driving market growth. Traditional treatments often involve medications or non-invasive interventions that may not provide satisfactory outcomes for all patients. In contrast, implantable sacral nerve stimulators offer a more targeted and personalized approach. By directly modulating nerve signals, these devices can achieve more precise and sustainable results, making them an appealing choice for patients and healthcare providers alike.
The sacral nerve stimulation market is segmented into product, application, end user, and region. On the basis of product, the market is bifurcated into devices and accessories. On the basis of application, it is categorized into urinary fecal incontinence, chronic anal fissure, and others (overactive bladder syndrome, urinary frequency). On the basis of end user, it is segregated into hospitals, specialty clinics, and others (research centers, ambulatory surgical centers). Region-wise, the market is analyzed across North America (the U. S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The key players profiled in the study include Medtronic Plc, Beijing PINS Medical Co., Ltd., Saluda Medical Pty Ltd., and Axonics, Inc. The players in the market have been actively engaged in the adoption various strategies such as product launch, acquisition and product approval to remain competitive and gain advantage over the competitors in the market. For instance, in February 2021, Medtronic plc, a global leader in healthcare technology, received approval from the United States Food and Drug Administration (FDA) for expanded MRI labeling of its InterStim II and InterStim Micro sacral neuromodulation (SNM) systems that use SureScan MRI leads. The updated MRI Guidelines allow for a wider range of MRI scan parameters and shorter wait time between MRI scans, thereby improving patient access to MRI exams and adding flexibility for MRI providers.
Key Market Insights
By product type, the devices segment accounted for the largest share in terms of revenue in 2022, and is expected to register the highest CAGR during the forecast period.On the basis of application, the urinary fecal incontinence segment was the major shareholder in terms of revenue in 2022 and is expected to register the highest CAGR during the forecast period.
Depending on end user, the hospitals segment garnered the largest share in terms of revenue in 2022, and is anticipated to register the highest CAGR during the forecast period.
Region-wise, North America occupied the largest share in terms of revenue in 2022. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
Companies Mentioned
- Axonics, Inc.
- Beijing PINS Medical Co., Ltd.
- Saluda Medical Pty Ltd.
- Medtronic plc
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
